NEW YORK, Dec. 4 – Affitech of Oslo and Axaron Bioscience of Heidelberg, Germany, said Tuesday that they had agreed to jointly develop and sel antibody drugs for neurological disorders. 

Axaron, formerly known as BASF-Lynx Bioscience, will use its transcription profiling technologies to identify targets that Affitech will then use in the development of antibodies. Both companies will support the effort to bring the antibodies through preclinical and clinical trials.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.